On July 27, 2026, the US Food and Drug Administration approved a second blood test for colorectal cancer screening: SimpleScreen CRC, developed by Freenome and set to be commercialized in the United States by Abbott from this fall. For anyone who has been putting off a colonoscopy or a stool kit, the headline sounds like a shortcut — a colon cancer blood test taken during an ordinary blood draw. The part that matters more is what such a test finds and what it misses. This article explains what the approval actually covers, how the result is read, and where a blood test fits next to the options already recommended.
What the FDA approved on July 27
The approval covers a screening test for adults aged 45 and older who are at average risk, have no symptoms, and are referred by a healthcare provider. It was evaluated in a prospective study that enrolled more than 48,000 adults across more than 200 sites, all of whom went on to have a screening colonoscopy so the blood result could be checked against what the camera found. Two points in the label deserve attention. A positive result is not a diagnosis: it is an instruction to book a colonoscopy. And the test is a screening tool for people with no warning signs, not an answer to symptoms such as rectal bleeding, a lasting change in bowel habit or unexplained weight loss, which need a medical assessment rather than a screening kit. Anyone weighing this up is better served by first understanding how colorectal cancer is detected and staged, then reading the result in that context, the way you would read any blood test result as part of a bigger picture.
How a colon cancer blood test works
Tumours shed tiny fragments of DNA into the bloodstream. These fragments circulate freely rather than inside cells, which is why they are called cell-free DNA, and a screening test of this kind looks for patterns in them that suggest a colorectal tumour is present. This is a different job from the tumour markers many people have already met on a lab report. CEA 및 CA 19-9 are used mainly to follow a cancer that is already known about, not to look for one in a healthy person, and that distinction runs through the whole family of tumour markers. The same technology sits behind the multi-cancer early detection tests that have been in the news, but a single-cancer screening test asks a narrower and easier question.
What it catches, and what it misses
Screening for colorectal cancer does two separate things. It finds cancers early, when treatment works best, and it finds the slow-growing precancerous polyps that can be removed before they ever turn into cancer. Blood tests are much better at the first job than the second. In validation studies, this class of test picked up roughly eight out of ten colorectal cancers, but only about one in eight of the advanced precancerous lesions that a colonoscopy or a good stool test would flag. Its specificity sits near nine in ten, which means around one person in ten with nothing serious will still get a positive result and need a colonoscopy to sort it out. None of that makes the test useless. It simply means a normal blood result is reassuring about cancer today and much less informative about the polyp that might matter in eight years. Separately, an unexplained low blood count on a routine panel remains a classic reason a doctor looks at the bowel, so it is worth knowing how anemia is investigated and what a 전혈구 검사(CBC) can and cannot show. Stool-based tests such as 분변 칼프로텍틴 answer different questions again, and a single out-of-range value is a prompt to look further rather than a verdict.
최신 연구 결과
Three threads of recent research explain why experts are enthusiastic and cautious at the same time. First, the clinical validation of this test, published in JAMA in 2025, confirmed the pattern above: solid detection of cancer that is already there, and a real struggle with advanced precancerous growths. The first approved blood test of this type, validated in the New England Journal of Medicine in 2024, behaved the same way. Second, a 2025 comparison from a large German screening cohort put a blood test side by side with the stool immunochemical test used across Europe, and the stool test came out clearly ahead for spotting precancerous lesions. A 2024 modelling study reached the practical version of that conclusion: a blood test only matches stool screening if it persuades substantially more people to get screened at all. Third, that is exactly what it seems to do. In a randomised trial published in 2024, adults who had already declined a stool kit were offered a blood test instead, and the share who ended up screened roughly doubled. The American Cancer Society weighed all of this in its 2026 guideline update and landed in a sensible place: blood tests are recommended, but they are not a preferred option, and they make most sense for people who decline or never complete the tests that work better. What this changes for you is simple. The best screening test is the one you will actually do, and a blood draw is a genuine option when the honest alternative is nothing at all.
Reading a colon cancer blood test result without panic
A screening result is a signpost, not a diagnosis. The table below offers a calm way to think it through.
| 해당 상황 | 가능한 의미 | 합리적인 다음 단계 |
|---|---|---|
| A positive screening blood test | Most positives turn out not to be cancer, but the signal has to be explained | Book a colonoscopy promptly, ideally within six months |
| A negative result, and you are due for screening | Reassuring for cancer today, weaker for precancerous polyps | Keep to the recommended interval and revisit the options with your doctor |
| Symptoms such as bleeding or a lasting change in bowel habit | This is no longer a screening situation | See a clinician for assessment rather than ordering a screening test |
| Family history, inflammatory bowel disease or previous polyps | You are above average risk, so the screening rules differ | Ask about a colonoscopy schedule tailored to your history |
Who this test is actually for
The clearest candidate is someone aged 45 or older, at average risk, with no symptoms, who has been offered a colonoscopy or a stool kit and has repeatedly not done either. For that person, a blood draw at a routine appointment converts a theoretical screening plan into a real one. The clearest non-candidates are people with symptoms, people already above average risk, and people who are happy to have a colonoscopy or complete a stool test, since those find precancerous growths far more reliably. Whatever route is chosen, one rule holds across all of them: a positive result on any test that is not a colonoscopy only counts as screening if the colonoscopy that follows actually happens. Coverage will also shape the decision in practice, since the approval means the test meets Medicare criteria for blood-based colorectal screening, while availability is expected to widen from the autumn.
용어 설명
- Cell-free DNA: small fragments of DNA circulating loose in the blood, some of which come from a tumour.
- Advanced precancerous lesion: a large or otherwise concerning polyp that has a meaningful chance of becoming cancer if it is left in place.
- Sensitivity: how often a test correctly flags people who do have the condition.
- Specificity: how often a test correctly stays negative in people who do not have the condition.
- Fecal immunochemical test: a stool test that detects hidden blood, used as the backbone of most organised screening programmes.
- Average risk: no symptoms, no personal or family history of colorectal cancer or advanced polyps, and no inflammatory bowel disease.
자주 묻는 질문
Can a blood test replace a colonoscopy for colon cancer screening?
Not as a preferred option. A blood test finds most cancers that are already present but misses the majority of advanced precancerous polyps, which is where colonoscopy and stool tests prevent cancer rather than just detecting it. Guidelines currently position blood testing as a fallback for people who will not do the preferred tests, and a positive result still leads to a colonoscopy.
How accurate is a colon cancer blood test?
In the studies used for approval, this class of test detected roughly eight in ten colorectal cancers and was negative in about nine in ten people without advanced disease. Its weak point is advanced precancerous lesions, where it flags only around one in eight. Accuracy therefore depends entirely on which of the two screening jobs you are asking it to do.
Who can get the newly approved test, and when?
It is indicated for adults aged 45 and over at average risk who are referred by a healthcare provider, and US commercialisation is expected from the autumn of 2026. It is not intended for people with symptoms or for those at higher risk because of family history, inflammatory bowel disease or previous polyps.
What happens if the blood test comes back positive?
The next step is a colonoscopy, preferably within six months. Most positive screening results do not turn out to be cancer, so a positive is best understood as a reason to complete the process rather than a diagnosis. Skipping the colonoscopy leaves the screening unfinished and removes most of its benefit.
출처
- Shaukat A, Burke CA, Chan AT, et al. Clinical Validation of a Circulating Tumor DNA-Based Blood Test to Screen for Colorectal Cancer. JAMA, 2025;334(1):56-63. doi.org/10.1001/jama.2025.7515
- Chung DC, Gray DM, Singh H, et al. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. New England Journal of Medicine, 2024;390(11):973-983. doi.org/10.1056/NEJMoa2304714
- Wolf AMD, Hoffman RM, Walter LC, et al. Colorectal cancer screening: an update to the American Cancer Society guideline, 2026. CA: A Cancer Journal for Clinicians, 2026;76(3):e70083. doi.org/10.3322/caac.70083
- Seum T, Hoffmeister M, Brenner H. Cell-free DNA blood-based test compared to fecal immunochemical test for colorectal cancer screening. Cancer Communications, 2025. consensus.app
- Coronado GD, et al. Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence. Gut, 2024. consensus.app
- Ladabaum U, et al. Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy. Gastroenterology, 2024. consensus.app
- American Cancer Society. Colorectal cancer screening guidelines. cancer.org
- Newitt P. FDA approves 2nd blood-based CRC screening test. Becker’s ASC, July 27, 2026. beckersasc.com
추가 읽을거리
- Colorectal cancer: symptoms, screening and treatment
- CEA blood test: how to read your results
- Multi-cancer early detection test: what the trial showed
- 혈액 검사 결과 읽는 법: 쉬운 가이드
- Anemia: symptoms, causes and tests
AI DiagMe로 내 검사 결과 이해하기
Screening reports are easier to face when every line is explained in plain language. AI DiagMe helps you see what markers such as CEA, CA 19-9 or a complete blood count mean together, so you read your results as a coherent picture rather than a single alarming line, and walk into your appointment with the right questions. It helps you understand your results and prepare for your visit; it does not diagnose and does not replace your doctor. 몇 분 안에 명확한 결과 해석 받기.
